Anna Holligan

Well, the reaction we can expect certainly from the hard right parties, including the farmer-citizen movement. So this is a farmer's party, often referred to as, and it came to power on a promise to protect farmers. And this is exactly the industry which is facing the biggest cuts. So inevitably, it's going to have a political impact, one of those parties.

Well, the reaction we can expect certainly from the hard right parties, including the farmer-citizen movement. So this is a farmer's party, often referred to as, and it came to power on a promise to protect farmers. And this is exactly the industry which is facing the biggest cuts. So inevitably, it's going to have a political impact, one of those parties.

sits within the newly formed coalition and they'll try to push back on any proposed changes that will impact upon the agriculture industry. But the cabinet as a whole now is under pressure from this court. A 10 million euro fine is at stake if they fail to meet those targets.

sits within the newly formed coalition and they'll try to push back on any proposed changes that will impact upon the agriculture industry. But the cabinet as a whole now is under pressure from this court. A 10 million euro fine is at stake if they fail to meet those targets.

Greenpeace had warned that the Netherlands' entire ecosystem is at risk of extinction if those high inflammations aren't cut. The government had said, you know, this is unrealistic, we can't achieve those targets. What the court said today was, well, actually, you are obliged to make this happen.

Greenpeace had warned that the Netherlands' entire ecosystem is at risk of extinction if those high inflammations aren't cut. The government had said, you know, this is unrealistic, we can't achieve those targets. What the court said today was, well, actually, you are obliged to make this happen.

We basically used a very novel way of preparing these samples and we are treating the DNA of the tumours that circulates in the plasma together with then looking and examining the entire genome that helps us to identify lots of different features of tumour DNA.

We basically used a very novel way of preparing these samples and we are treating the DNA of the tumours that circulates in the plasma together with then looking and examining the entire genome that helps us to identify lots of different features of tumour DNA.

That's correct. They're very small fragments of DNA that are shredded by tumours, even by early stage tumours. And it's those fragments of tumor DNA that you can identify from a simple blood draw. That's what we are examining, simply because we think that that is where tumor originates from. It's ultimately a problem with changes in the DNA.

That's correct. They're very small fragments of DNA that are shredded by tumours, even by early stage tumours. And it's those fragments of tumor DNA that you can identify from a simple blood draw. That's what we are examining, simply because we think that that is where tumor originates from. It's ultimately a problem with changes in the DNA.

And then importantly, we can detect imprinting of the DNA that happens very early on that is quite tissue specific. So when you have a pancreas cancer, for example, you can then go back and you can say, oh, this is really... coming from the pancreas. So that allows us to do a tissue of origin estimation.

And then importantly, we can detect imprinting of the DNA that happens very early on that is quite tissue specific. So when you have a pancreas cancer, for example, you can then go back and you can say, oh, this is really... coming from the pancreas. So that allows us to do a tissue of origin estimation.

Yes, ultimately it will help us identify where the cancer is, which tissue it originates from, but really putting all those different attributes together and then training the algorithms to detect them. That is really where I think the innovation is.

Yes, ultimately it will help us identify where the cancer is, which tissue it originates from, but really putting all those different attributes together and then training the algorithms to detect them. That is really where I think the innovation is.

So it ultimately depends a lot on the cost of the test and how many tests you have to perform. So that's a health economic question and it depends on how much payers are willing to pay. When it comes to resource restricted environments or public health system, then one would say that it complements current existing screening programs, but these are invasive They use radiology.

So it ultimately depends a lot on the cost of the test and how many tests you have to perform. So that's a health economic question and it depends on how much payers are willing to pay. When it comes to resource restricted environments or public health system, then one would say that it complements current existing screening programs, but these are invasive They use radiology.

You have to undergo endoscopy. The uptake of these screening programmes is only about 60% overall. So using this as a complement to people who would otherwise not undergo any screening, I think that would be already a success.

You have to undergo endoscopy. The uptake of these screening programmes is only about 60% overall. So using this as a complement to people who would otherwise not undergo any screening, I think that would be already a success.

We are slap bang in the middle of New Orleans. There's Bourbon Street, which many people will have heard of. It's the most famous street. Partying for bars, for restaurants, for music. And I was out here last night and it was absolutely thronged with people. And to get a sense of what it's like here in New Orleans is that's not unusual.

We are slap bang in the middle of New Orleans. There's Bourbon Street, which many people will have heard of. It's the most famous street. Partying for bars, for restaurants, for music. And I was out here last night and it was absolutely thronged with people. And to get a sense of what it's like here in New Orleans is that's not unusual.